India Advances TB Fight with Novel Vaccines

India is at the forefront of developing new tools to combat tuberculosis, a disease that remains a significant public health challenge. Two novel vaccines, VPM1002 by Serum Institute of India and Immuvac by Cadila, have shown promising results in large-scale clinical trials. These trials, independently led and funded by the Indian Council of Medical Research (ICMR), focused on their efficacy and safety.

The Phase III trial involved over 12,700 participants and yielded significant findings, particularly against extra-pulmonary TB, a severe form of the disease that affects organs beyond the lungs. VPM1002 demonstrated a 50.4% efficacy against extra-pulmonary TB, offering critical hope for reducing deaths and disability. The trial's design, reflecting real-world conditions, and ICMR's oversight lend strong credibility to the results.

Furthermore, the potential for these vaccines to be produced at a low cost, possibly under one hundred rupees per dose, makes them a viable addition to India's TB control strategy. This affordability is key to large-scale preventive vaccination efforts. Experts suggest these vaccines, combined with early diagnosis and treatment, could significantly advance India's goal of eliminating TB by 2025.